Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension

Eur Rev Med Pharmacol Sci. 2014;18(5):630-7.


Objectives: The aim of this study was to investigate if the new generation beta-blockers are as effective as irbesartan, which is an angiotensin receptor blocker (ARB), on left ventricular hypertrophy (LVH).

Patients and methods: The study included 85 patients (average age: 56.6±9.6 year) with stage 1 and 2 hypertension, who previously didn't receive an antihypertensive treatment, but diagnosed with LVH echocardiographically. The patients were divided into three different treatment groups: irbesartan (n=28), nebivolol (n=25) and carvedilol (n=32). The patients were reassessed clinically and echocardiographically at 3, 6 and 12 months after the treatments.

Results: There was no statistically significant difference in baseline left ventricular mass index (LVMI) and other parameters among the three treatment groups (p > 0.05). Although there was no significant decrease in LVMI in irbesartan and carvedilol groups at 3 months after the treatment (p > 0.05), the values measured at 6 and 12 months (p < 0.0001) were significant. The decrease in LVMI in the nebivolol group was significant at 3, 6 and 12 months (p < 0.0001). There was a significant difference in measurements at 12 months (p < 0.05).

Conclusions: Both of the new generation beta-blockers were more effective than irbesartan in the regression of LVH. A significant regression in LVH was observed 3 months after nebivolol treatment and 6 months after irbesartan and carvedilol treatments.

Publication types

  • Comparative Study

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Biphenyl Compounds
  • Carbazoles / therapeutic use*
  • Carvedilol
  • Cohort Studies
  • Female
  • Humans
  • Hypertension / diagnostic imaging*
  • Hypertension / drug therapy*
  • Hypertension / epidemiology
  • Hypertrophy, Left Ventricular / diagnostic imaging*
  • Hypertrophy, Left Ventricular / drug therapy*
  • Hypertrophy, Left Ventricular / epidemiology
  • Irbesartan
  • Male
  • Middle Aged
  • Nebivolol / therapeutic use*
  • Propanolamines / therapeutic use*
  • Prospective Studies
  • Tetrazoles
  • Treatment Outcome
  • Ultrasonography


  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Biphenyl Compounds
  • Carbazoles
  • Propanolamines
  • Tetrazoles
  • Nebivolol
  • Carvedilol
  • Irbesartan